Sandoz announced the US launch of generic Icatibant injection pre-filled syringe to treat acute attacks of rare disease hereditary angioedema (HAE) in adults 18 years and older. It is available immediately for US patients. Sandoz has signed a US commercialization deal with Slayback Pharma, a company focused on producing complex generic and specialty pharmaceutical products, for this medicine, which is a generic equivalent to Takeda's Firazyr®* (icatibant injection). Hereditary angioedema is a rare disease characterized by recurrent episodes of severe swelling of the skin and mucous membranes. Swelling of the airways and throat can be extremely dangerous and potentially lead to death. Patients can also suffer nausea, vomiting, diarrhea and abdominal pain.